Comparison of Clinical Outcomes in Patients with Active Cancer Receiving Rivaroxaban or Low Molecular Weight Heparin - The OSCAR-UK Study.
Alexander CohenChristopher WallenhorstMarcela RiveraCihan AyBernhard SchaeferKhaled AbdelgawwadGeorge PsaroudakisGunnar BrobertAnders EkbomAgnes Y Y LeeAlok A KhoranaCecilia BecattiniMarc CarrierCraig I ColemanCarlos MartinezPublished in: Thrombosis and haemostasis (2024)
Patients with CAT, not at high risk of bleeding, treated with either rivaroxaban or LMWH have comparable effectiveness and safety outcomes. This supports the recommendation that rivaroxaban is a reasonable alternative to LMWH for the treatment of CAT.